Free Trial

Corvus Pharmaceuticals (CRVS) Competitors

Corvus Pharmaceuticals logo
$3.94 -0.05 (-1.13%)
Closing price 07/3/2025 02:54 PM Eastern
Extended Trading
$3.96 +0.02 (+0.51%)
As of 07/3/2025 04:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRVS vs. PAHC, WVE, ELVN, VERV, NTLA, COLL, AKBA, SYRE, MLYS, and AVDL

Should you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Phibro Animal Health (PAHC), WAVE Life Sciences (WVE), Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), Intellia Therapeutics (NTLA), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry.

Corvus Pharmaceuticals vs. Its Competitors

Phibro Animal Health (NASDAQ:PAHC) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

Phibro Animal Health has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.

Phibro Animal Health currently has a consensus price target of $21.80, indicating a potential downside of 22.12%. Corvus Pharmaceuticals has a consensus price target of $15.00, indicating a potential upside of 281.19%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Phibro Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Phibro Animal Health
2 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Corvus Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Phibro Animal Health has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phibro Animal Health$1.02B1.11$2.42M$0.7835.88
Corvus PharmaceuticalsN/AN/A-$62.29M-$0.98-4.02

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by insiders. Comparatively, 28.5% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Phibro Animal Health had 3 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 5 mentions for Phibro Animal Health and 2 mentions for Corvus Pharmaceuticals. Phibro Animal Health's average media sentiment score of 0.25 beat Corvus Pharmaceuticals' score of -0.10 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Phibro Animal Health
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Corvus Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Phibro Animal Health has a net margin of 2.68% compared to Corvus Pharmaceuticals' net margin of 0.00%. Phibro Animal Health's return on equity of 30.51% beat Corvus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Phibro Animal Health2.68% 30.51% 6.89%
Corvus Pharmaceuticals N/A -24.04%-13.90%

Summary

Phibro Animal Health beats Corvus Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Get Corvus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRVS vs. The Competition

MetricCorvus PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$269.27M$2.91B$5.56B$9.04B
Dividend YieldN/A2.44%5.22%3.99%
P/E Ratio-4.0221.5627.6620.25
Price / SalesN/A283.36423.00177.43
Price / CashN/A42.7336.8958.10
Price / Book7.727.518.035.67
Net Income-$62.29M-$55.14M$3.18B$249.21M
7 Day Performance1.16%4.61%2.93%3.28%
1 Month Performance0.64%0.90%1.72%3.95%
1 Year Performance116.21%5.40%34.39%20.98%

Corvus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRVS
Corvus Pharmaceuticals
2.4724 of 5 stars
$3.94
-1.1%
$15.00
+281.2%
+116.2%$269.27MN/A-4.0230Insider Trade
PAHC
Phibro Animal Health
3.6492 of 5 stars
$25.54
-0.5%
$21.80
-14.6%
+66.1%$1.04B$1.02B32.741,940
WVE
WAVE Life Sciences
4.3635 of 5 stars
$6.50
-2.5%
$20.50
+215.4%
+27.4%$1.04B$108.30M-7.74240News Coverage
ELVN
Enliven Therapeutics
2.5165 of 5 stars
$20.06
-3.0%
$39.60
+97.4%
-7.8%$1.01BN/A-10.4550Analyst Forecast
Analyst Revision
VERV
Verve Therapeutics
3.4265 of 5 stars
$11.23
-0.6%
$14.57
+29.8%
+113.8%$1.01B$32.33M-5.32110
NTLA
Intellia Therapeutics
4.7205 of 5 stars
$9.38
-1.9%
$33.37
+255.7%
-52.9%$990.25M$57.88M-1.79600News Coverage
COLL
Collegium Pharmaceutical
4.2729 of 5 stars
$29.57
-1.2%
$43.75
+48.0%
-5.6%$961.71M$631.45M24.24210News Coverage
Analyst Downgrade
AKBA
Akebia Therapeutics
4.2551 of 5 stars
$3.64
-0.3%
$6.75
+85.4%
+285.3%$958.62M$160.18M-17.33430Insider Trade
SYRE
Spyre Therapeutics
1.5633 of 5 stars
$14.97
-1.6%
$53.40
+256.7%
-37.9%$917.39M$890K-3.9773News Coverage
MLYS
Mineralys Therapeutics
2.1568 of 5 stars
$13.53
-1.3%
$32.25
+138.4%
+16.9%$893.55MN/A-3.6328
AVDL
Avadel Pharmaceuticals
2.424 of 5 stars
$8.85
-3.8%
$18.17
+105.3%
-39.6%$890M$169.12M-32.7870

Related Companies and Tools


This page (NASDAQ:CRVS) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners